{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:35:39Z","timestamp":1773963339301,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004820","name":"Mochida Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacl.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:20:56Z","timestamp":1765725656000},"page":"289-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China"],"prefix":"10.1016","volume":"20","author":[{"given":"Yanfang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-7505","authenticated-orcid":false,"given":"Wang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacl.2025.12.007_bib0001","first-page":"221","article-title":"Chinese guidelines for lipid management","volume":"51","author":"Li","year":"2023","journal-title":"Chin J Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2025.12.007_bib0002","first-page":"833","article-title":"Chinese guideline for the management of dyslipidemia in adults (2016 Revision)","volume":"44","year":"2016","journal-title":"Chin J Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2025.12.007_bib0003","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.007_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.007_bib0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","article-title":"Hypertriglyceridemia","volume":"19","author":"Pejic","year":"2006","journal-title":"J Am Board Fam Med"},{"issue":"9943","key":"10.1016\/j.jacl.2025.12.007_bib0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2025.12.007_bib0007","first-page":"949","article-title":"Report on Cardiovascular Health and Diseases in China 2023: an updated summary","volume":"37","year":"2024","journal-title":"Biomed Environ Sci"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.007_bib0008","first-page":"347","article-title":"Management of hypertriglyceridemia: common questions and answers","volume":"102","author":"Oh","year":"2020","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.007_bib0009","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome-causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.jacl.2025.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3748\/wjg.15.1427","article-title":"Acute pancreatitis: etiology and common pathogenesis","volume":"15","author":"Wang","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12876-018-0821-z","article-title":"Significantly different clinical features between hypertriglyceridemia and biliary acute pancreatitis: a retrospective study of 730 patients from a tertiary center","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74943-8","article-title":"Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis","volume":"10","author":"B\u00e1lint","year":"2020","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.jacl.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2025.12.007_bib0014","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China guidelines for lipid management","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.007_bib0015","first-page":"819","article-title":"Clinical usefulness of ethyl icosapentate (EPA-E) in hyperlipidemia: comparison with clinofibrate in a double-blind study","volume":"30","author":"Hata","year":"1992","journal-title":"Ronen Igaku [Jpn J Geriatr]"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.007_bib0016","first-page":"799","article-title":"Long-term clinical usefulness of ethyl icosapentate (EPA-E, MND-21) in hyperlipidemia","volume":"30","author":"Hata","year":"1992","journal-title":"Ronen Igaku [Jpn J Geriatr]"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.007_bib0017","first-page":"1293","article-title":"Clinical pharmacological study of ethyl icosapentate (MND-21): optimal dosage","volume":"8","author":"Goto","year":"1992","journal-title":"Rinsho Iyaku [Clin Pharmacol Ther Jpn]"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.007_bib0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1254\/fpj.91.255","article-title":"Pharmacological studies of ethyl eicosapentaenoate (EPA-E) in high cholesterol diet-fed rabbits","volume":"91","author":"Mizota","year":"1988","journal-title":"Nippon Yakurigaku Zasshi [Folia Pharmacol Jpn]"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005344-199307000-00001","article-title":"Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on the physical properties of arterial walls in high cholesterol diet-fed rabbits","volume":"22","author":"Sato","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2025.12.007_bib0020","article-title":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Size, shape, and other physical attributes of generic tablets and capsules","year":"2022","journal-title":"Guidance for industry"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41898","article-title":"Effectiveness of a novel \u03c9-3 Krill oil agent in patients with severe hypertriglyceridemia: a randomized clinical trial","volume":"5","author":"Mozaffarian","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"22","key":"10.1016\/j.jacl.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids versus corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12944-023-01838-8","article-title":"Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China","volume":"22","author":"Wang","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0026","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa for lowering very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"5-6","key":"10.1016\/j.jacl.2025.12.007_bib0027","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","article-title":"Safety and efficacy of Omacor in severe hypertriglyceridemia","volume":"4","author":"Harris","year":"1997","journal-title":"J Cardiovasc Risk"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.007_bib0028","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/ehjcvp\/pvab008","article-title":"Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Lombardi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6 Suppl","key":"10.1016\/j.jacl.2025.12.007_bib0029","doi-asserted-by":"crossref","first-page":"1467S","DOI":"10.1093\/ajcn\/83.6.1467S","article-title":"Distribution, interconversion, and dose response of n - 3 fatty acids in humans","volume":"83","author":"Arterburn","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.007_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"9567","key":"10.1016\/j.jacl.2025.12.007_bib0031","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.007_bib0032","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013 statin and eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.007_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-019-0763-0","article-title":"Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials","volume":"21","author":"Jia","year":"2019","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.007_bib0034","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CP9.0000000000000102","article-title":"Impact of eicosapentaenoic acid on cardiovascular outcomes after acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Fallahtafti","year":"2024","journal-title":"Cardiol Plus"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.007_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2025.12.007_bib0036","article-title":"ACC news story; REDUCE-IT EPA trial shows association between higher EPA levels","year":"2020","journal-title":"Reduced CV Events"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:54:04Z","timestamp":1773953644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1933287425005392"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}